Report
Paul Bryant

FY25 expected to be materially above expectations

In today’s FY25 year-end trading summary for the period 1 Apr 24 – 31 Mar 25, Mercia has announced it expects EBITDA to be ‘materially ahead’ of expectations. This seems to be driven by a ‘continuing focus on efficiencies.’ It also reported a jump in net inflows in Q4 (£250m). This is hugely impressive given such an uncertain market and economic environment.

It closed the year with cash and equivalents of c. £40m, well ahead of our forecast of £34m. Following the recent share price fall, that £40m of cash translates to around 31% of Mercia’s market cap. We.Provided there are no major falls in the NAV of on-balance-sheet investments, today’s update suggests that our previous sum-of-the-parts valuation of 52p per share (double the current share price) may prove conservative.

The £250m of inflows in Q4 (existing fund mandate increases, new fund management contracts, and successful VCT and EIS fund raises), coupled with the £57m in H1 shows that Mercia has developed a proposition which is highly attractive to investors in its range of vehicles.

We upgrade FY25 forecasts on the back of higher-than-expected net flows and additional efficiencies, and assume no major market moves in FUM, or large valuation moves to on-balance investments. Our fundamental valuation of 52p / share is unchanged for now.
Underlying
Mercia Asset Management

Mercia Technologies is an investment group focused on the creation/identification, funding and scaling of technology businesses from the U.K. regions. Co. directly invests across four sectors: Software & the Internet, which consists of cyber security, software as a service analytical tool, Adtech and artificial intelligence; Digital & Digital Entertainment, which consists of virtual reality, augmented reality, mixed reality and serious games; Electronics, Materials & Manufacturing/Engineering, which consists of energy and communications, value electronics, and manufacturing applications; and Life Sciences & Biosciences, which consists of diagnostics, digital health and medical devices.

Provider
Equity Development
Equity Development

​Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.

Analysts
Paul Bryant

Other Reports on these Companies
Other Reports from Equity Development

ResearchPool Subscriptions

Get the most out of your insights

Get in touch